Matthew H Secrest (M H Secrest)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 6

Top Topics

Artificial Intelligence

Tyrosine Kinase

Electronic Health Record

Top Venues

Pharmacoepidemiology and drug safety

Future oncology (London, England)

European journal of haematology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael B Atkins, Cristina Julian, Matthew H Secrest, Janet Lee, Ana M Abajo-Guijarro, Edward McKenna
Real-world treatment patterns and overall survival in BRAF -mutant melanoma patients treated with immunotherapy or targeted therapy. Future oncology (London, England) 18 (18) (2022)
Matthew H Secrest, Mike Storm, Courtney Carrington, Deborah Casso, Keely Gilroy, Leanne Pladson, Audra N Boscoe
Prevalence of pyruvate kinase deficiency: A systematic literature review. European journal of haematology 105 (2) (2020)
Matthew H Secrest, Robert W Platt, Colin R Dormuth, Dan Chateau, Laura Targownik, Rui Nie, Carla M Doyle, Sophie Dell'Aniello, Kristian B Filion
Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. Pharmacoepidemiology and drug safety (2019)
Matthew H Secrest, Robert W Platt, Pauline Reynier, Colin R Dormuth, Andrea Benedetti, Kristian B Filion
Multiple imputation for systematically missing confounders within a distributed data drug safety network: A simulation study and real-world example. Pharmacoepidemiology and drug safety (2019)
Matthew H Secrest, Laurent Azoulay, Matthew Dahl, Kristin K Clemens, Madeleine Durand, Nianping Hu, Laura Targownik, Tanvir C Turin, Colin R Dormuth, Kristian B Filion
A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns. Pharmacoepidemiology and drug safety (2019)
Matthew H Secrest, J J Schauer, E M Carter, J Baumgartner
Particulate matter chemical component concentrations and sources in settings of household solid fuel use. Indoor air 27 (6) (2017)